Evidence map›Paper›PMID 39915674›Full record

ArticleCommunications biology2025

Development of tolerance to bedaquiline by overexpression of trypanosomal acetate: succinate CoA transferase in Mycobacterium smegmatis.

Gloria Mavinga Bundutidi, Kota Mochizuki, Yuichi Matsuo, Mizuki Hayashishita, Takaya Sakura, Yuri Ando, Gregory Murray Cook, Acharjee Rajib, Frédéric Bringaud, Michael Boshart and 5 more

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Microorganisms · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Gloria Mavinga BundutidiProgram for Nurturing Global Leaders in Tropical and Emerging Communicable Disease, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Kota MochizukiDepartment of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.ORCID http://orcid.org/0000-0002-2335-1503
Yuichi MatsuoSchool of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.
Mizuki HayashishitaSchool of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.
Takaya SakuraDepartment of Molecular Infection Dynamics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Yuri AndoDepartment of Infectious Disease Control, Oita University, Oita, Japan.
Gregory Murray CookDepartment of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.ORCID http://orcid.org/0000-0001-8349-1500
Acharjee RajibDepartment of Molecular Infection Dynamics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Frédéric BringaudLaboratoire de Microbiologie Fondamentale et Pathogénicité (MFP), Université de Bordeaux, Bordeaux, France.ORCID http://orcid.org/0000-0003-4552-6877
Michael BoshartFakultät für Biologie, Genetik, Ludwig-Maximilians-Universität München, München, Germany.ORCID http://orcid.org/0000-0002-5070-2663
Shinjiro HamanoProgram for Nurturing Global Leaders in Tropical and Emerging Communicable Disease, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.ORCID http://orcid.org/0000-0003-3881-8337
Masakazu SekijimaDepartment of Computer Science, Institute of Science Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3806-9535
Kenji HirayamaDepartment of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Kiyoshi KitaSchool of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.
Daniel Ken InaokaDepartment of Molecular Infection Dynamics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan. danielken@nagasaki-u.ac.jp.ORCID http://orcid.org/0000-0002-9791-927X

Funding

Ministry of Education, Culture, Sports, Science and Technology (MEXT) Grants-in-aid for Scientific Research (A) 20H00620
6 · The paper itself

Abstract

The F-type ATP synthase inhibitor bedaquiline (BDQ) is a potent inhibitor of mycobacterial growth and this inhibition cannot be rescued by fermentable carbon sources that would supply ATP by an alternative pathway (substrate level phosphorylation). To gain mechanistic insight into this phenomenon, we employed a metabolic engineering approach. We introduced into Mycobacterium smegmatis an alternative ATP production pathway by substrate-level phosphorylation, specifically through overexpression of trypanosomal acetate:succinate co-enzyme A (CoA) transferase (ASCT). Intriguingly, the overexpression of ASCT partially restored intracellular ATP levels and resulted in acquired tolerance to BDQ growth inhibition at low, but not high concentrations of BDQ. These results implicate intracellular ATP levels in modulating the growth inhibitory activity of BDQ at low concentrations. These findings shed light on the intricate interplay between BDQ and mycobacterial energy metabolism, while also providing a novel tool for the development of next-generation ATP synthase-specific inhibitors targeting mycobacteria.

Indexed as

Antitubercular AgentsCoenzyme A-TransferasesDiarylquinolinesMycobacterium smegmatisAdenosine TriphosphateBacterial ProteinsAdenosine TriphosphateAntitubercular AgentsBacterial ProteinsbedaquilineCoenzyme A-TransferasesDiarylquinolines

Identifiers

PMID39915674
PMCPMC11802737

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.